


Company registration number: **10166574**

**R-Evolution Worldwide Community Interest
Company**

UNAUDITED FILLETED FINANCIAL STATEMENTS

for the year ended 30 April 2023

THURSDAY



ACHD4GRM

A03

30/11/2023

#45

COMPANIES HOUSE

R-Evolution Worldwide Community Interest Company

Statement of Financial Position

30 April 2023

	Note	2023 £	2022 £
Fixed assets			
Investments	5	2,288	2,288
Current assets			
Debtors	6	3,718	1,246
Cash at bank and in hand		215,282	286,410
		<u>219,000</u>	<u>287,656</u>
Creditors: amounts falling due within one year	7	<u>(19,396)</u>	<u>(78,770)</u>
Net current assets		<u>199,604</u>	<u>208,886</u>
Total assets less current liabilities		<u>201,892</u>	<u>211,174</u>
Creditors: amounts falling due after more than one year	8	<u>(2,701)</u>	<u>(4,092)</u>
Net assets		<u><u>199,191</u></u>	<u><u>207,082</u></u>
Capital and reserves			
Called up share capital		1,000	1,000
Profit and loss account		<u>198,191</u>	<u>206,082</u>
Shareholders funds		<u><u>199,191</u></u>	<u><u>207,082</u></u>

For the year ending 30 April 2023, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered.


The notes on pages 3 to 6 form part of these financial statements.

R-Evolution Worldwide Community Interest Company

Statement of Financial Position (continued)

30 April 2023

These financial statements were approved by the board of directors and authorised for issue on 20 November 2023, and are signed on behalf of the board by:

A handwritten signature in black ink, appearing to read 'D Scaramuzzi', is written over a horizontal line.

D Scaramuzzi

Director

Company registration number: 10166574

The notes on pages 3 to 6 form part of these financial statements.

R-Evolution Worldwide Community Interest Company

Notes to the Financial Statements

Year ended 30 April 2023

1 General information

The company is a private company limited by shares and is registered in England and Wales. The address of the registered office is St Marks Studios, 16, Chillingworth Road, London, N7 8QJ, United Kingdom.

2 Statement of compliance

These financial statements have been prepared in compliance with FRS 102 Section 1A, 'The Financial Reporting Standard applicable to the UK and Republic of Ireland'.

3 Accounting policies

BASIS OF PREPARATION

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain assets.

The financial statements are prepared in British pound sterling, which is the functional currency of the company.

FOREIGN CURRENCY TRANSLATION

The transactions denominated in foreign currency are translated into sterling and recorded at the rate of exchange ruling at the date of the transaction.

Balances at the year end denominated in a foreign currency are translated at the rate of exchange ruling at the balance sheet date

TURNOVER

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and Value Added Tax. Turnover includes revenue earned from the rendering of clinical and biomedical research services.

Rendering of services

Turnover from the rendering of clinical and biomedical research services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.

TAXATION

Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit.

R-Evolution Worldwide Community Interest Company

Notes to the Financial Statements (continued)

Year ended 30 April 2023

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

FIXED ASSET INVESTMENTS

Investments in subsidiaries, associates and joint ventures accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses.

Investments in subsidiaries, associates and joint ventures accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income or profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted.

Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.

Other fixed asset investments which are listed are measured at fair value with changes in fair value being recognised in profit or loss.

All other Investments held as fixed assets are initially recorded at cost, and are subsequently stated at cost less any accumulated impairment losses.

IMPAIRMENT

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

GRANTS

Grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received.

Grants are recognised using the accrual model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the entity recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income

R-Evolution Worldwide Community Interest Company

Notes to the Financial Statements (continued)

Year ended 30 April 2023

and not deducted from the carrying amount of the asset.

FINANCIAL INSTRUMENTS

Basic financial instruments are recognised at amortised cost, except for investments in non convertible preference and non puttable ordinary shares which are measured at fair value with changes recognised in the profit and loss. Derivative financial instruments are initially recorded at cost and there after at fair value with changes recognised in the profit and loss.

4 Average number of employees

The average number of persons employed by the company during the year was Nil (2022: Nil).

5 Investments

	Shares in group undertakings and participating interests
	£
Cost	
At 1 May 2022	2,288
At 30 April 2023	2,288
Impairment	
At 1 May 2022 and 30 April 2023	-
Carrying amount	
At 30 April 2023	2,288
At 30 April 2022	2,288

R-Evolution Worldwide Community Interest Company

Notes to the Financial Statements (continued)

Year ended 30 April 2023

6 Debtors

	2023	2022
	£	£
Other debtors	3,718	1,246

7 Creditors: amounts falling due within one year

	2023	2022
	£	£
Trade creditors	-	369
Taxation and social security	-	5,418
Other creditors	19,396	72,983
	19,396	78,770

8 Creditors: amounts falling due after more than one year

	2023	2022
	£	£
Other creditors	2,701	4,092

CIC 34

Community Interest Company Report

For official use
(Please leave blank)

--

*Please
complete in
typescript, or
in bold black
capitals.*

Company Name in
full

REVOLUTION WORLDWIDE COMMUNITY
INTEREST COMPANY

Company Number

10166574

Year Ending

30/04/2023

PART 1 - GENERAL DESCRIPTION OF THE COMPANY'S ACTIVITIES AND IMPACT

In the space provided below, please insert a general account of the company's activities in the financial year to which the report relates, including a description of how they have benefited the community.

The Company extended its involvement in humanitarian welfare for the populations living in middle-low income countries also in Mali and Burkina Faso, where is conducting a campaign to prevent malaria in pregnant women and children.

The Company is still involved in Congo-Brazzaville, where provided an intervention aimed at improving hygiene and prevention of infectious diseases in the orphanage of "Yamba Ngai", located in Brazzaville, Republic of Congo.

The Company also is continuing collaboration with "La maison de Bruna et Luigi", a healthcare center in Kinshasa – DRC, hosting children with handicapped and with cerebral palsy.

The Company also kept its commitment in Sierra Leone (West Africa), were supported the activities of a Local Voluntary Organization of Sierra Leoneans aimed at helping vulnerable communities as children, youth and women.

The Company also supported the already established not-for-profit association of volunteers in Uganda, registered to the local administrative authorities as "R-Evolution for the Children and Vulnerable". Also this organization is aimed at improving hygiene and prevention of infectious diseases in the orphanages.

The communities of the vulnerable children benefitted from these above described activities as less exposed preventable, often deadly, infectious diseases.

The activities of the Company continued also in other African countries, in particular in Tanzania, Zambia, Mali, Burkina Faso, Liberia, Republic of Congo, Cameroon, Democratic Republic of Congo, Chad, Gabon, Republic of Central Africa, Mozambique, Botswana, Lesotho and Eswatini. In these countries the Company developed with the Ministries of Health, National Medicines Regulatory Authorities, National Ethics Committees and public health research networks 5 projects to increase the capacity for a biomedical research able to address the local public health needs. These projects (INTEGRATION, NeuroSolve, LiberHetica, Africlinique, AfriEthique, SEARCH, ITAIL-COVID-19) received also a favourable opinion for funding from the European Commission (EC/EDCTP) focused on clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa.

During the relevant financial year, the company activities have benefited the communities, including the most vulnerable populations, in the following ways:

- In Liberia, Republic of Congo, Cameroon, Democratic Republic of Congo, Chad, Gabon, Republic of Central Africa, Mozambique, Botswana, Lesotho, eSwatini, Mali and Burkina Faso where the populations are relying on improved clinical research for new treatments addressing the public health needs, with the ultimate goal to address the United Nations Sustainable Development Goal n. 3: "Ensure healthy lives and promote well-being for all at all ages"
- In Republic of Congo, Democratic Republic of Congo, Sierra Leone and Uganda, where the most neglected populations represented by the orphans are involved in the interventions

The staff of the orphanages will be better trained on children care

The orphans with acute health problems have been visited and treated

The orphans with chronic health problem got their first ever medical visit and then referred to the appropriate care path

The orphans with disabilities got their first ever medical visit and referred to an appropriate physiotherapy and rehabilitation path.

The caregivers involved in the orphanage received both healthcare and children dietary training.

(Please continue on separate continuation sheet if necessary.)

PART 2 – CONSULTATION WITH STAKEHOLDERS – Please indicate who the company's stakeholders are; how the stakeholders have been consulted and what action, if any, has the company taken in response to feedback from its consultations? If there has been no consultation, this should be made clear.

The Company's stakeholders are the heads and the managers of the organizations and institutions involved in the activities described in the PART 1. They were consulted firstly by email, calls, and web meeting (due to geographical distances), and then by face to face meetings when possible. These consultations were important to understand the needs and areas of intervention. Consequently, the actions of the Company were focused to the healthcare of vulnerable communities.

(If applicable, please just state "A social audit report covering these points is attached").

PART 3 – DIRECTORS' REMUNERATION – if you have provided full details in your accounts you need not reproduce it here. Please clearly identify the information within the accounts and confirm that, "There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director's loss of office, which require to be disclosed" (See example with full notes). If no remuneration was received you must state that "no remuneration was received" below.

There were no transactions or arrangements in connection with the remuneration of directors, or compensation for director's loss of office, which require to be disclosed.

PART 4 – TRANSFERS OF ASSETS OTHER THAN FOR FULL CONSIDERATION – Please insert full details of any transfers of assets other than for full consideration e.g. Donations to outside bodies. If this does not apply you must state that "no transfer of assets other than for full consideration has been made" below.


No transfer of assets other than for full consideration has been made.

(Please continue on separate continuation sheet if necessary.)

PART 5 – SIGNATORY

The original report must be signed by a director or secretary of the company

Signed



Date

20/11/23

Office held (delete as appropriate) Director/Secretary

You do not have to give any contact information in the box opposite but if you do, it will help the Registrar of Companies to contact you if there is a query on the form. The contact information that you give will be visible to searchers of the public record.

Tel	
DX Number	DX Exchange

When you have completed and signed the form, please attach it to the accounts and send both forms by post to the Registrar of Companies at:

For companies registered in England and Wales: Companies House, Crown Way, Cardiff, CF14 3UZ
DX 33050 Cardiff

For companies registered in Scotland: Companies House, 4th Floor, Edinburgh Quay 2, 139
Fountainbridge, Edinburgh, EH3 9FF DX 235 Edinburgh or LP – 4 Edinburgh 2

For companies registered in Northern Ireland: Companies House, 2nd Floor, The Linenhall, 32-38
Linenhall Street, Belfast, BT2 8BG